David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$696M |
| 2 |
Apple
AAPL
|
+$379M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$289M |
| 4 |
Keurig Dr Pepper
KDP
|
+$275M |
| 5 |
Meta Platforms (Facebook)
META
|
+$241M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TWX
Time Warner Inc
TWX
|
+$648M |
| 2 |
Merck
MRK
|
+$453M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$390M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$273M |
| 5 |
Broadcom
AVGO
|
+$265M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.15% |
| 2 | Consumer Discretionary | 12.62% |
| 3 | Healthcare | 10.65% |
| 4 | Financials | 9.26% |
| 5 | Industrials | 6.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
Tetra Tech
TTEK
$9.42B
| $971K | ﹤0.01% |
83,000
-2,975
| -3% | -$31.8K |
|
|
GBNK
2677
DELISTED
Guaranty Bancorp
GBNK
| $970K | ﹤0.01% |
32,528
+14,023
| +76% | +$430K |
|
2678
Viking Therapeutics
VKTX
$3.99B
| $967K | ﹤0.01% |
+101,846
| New | +$677K |
|
2679
PUT
PTC
PTC
$16.4B
| $966K | ﹤0.01% |
+10,300
| New | +$891K |
|
2680
Morningstar
MORN
$8.07B
| $959K | ﹤0.01% |
7,476
+1,600
| +27% | +$183K |
|
2681
CALL
Tyson Foods
TSN
$20.1B
| $957K | ﹤0.01% |
13,900
+9,200
| +196% | +$640K |
|
2682
PUT
Ichor Holdings
ICHR
$2.14B
| $955K | ﹤0.01% |
+45,000
| New | +$1.07M |
|
2683
Geospace Technologies
GEOS
$72.3M
| $952K | ﹤0.01% |
67,729
-6,023
| -8% | -$69.8K |
|
|
CRHM
2684
DELISTED
CRH Medical Corporation
CRHM
| $950K | ﹤0.01% |
303,900
+144,500
| +91% | +$461K |
|
2685
PUT
Adient
ADNT
$1.44B
| $949K | ﹤0.01% |
+19,300
| New | +$1.1M |
|
2686
Teleflex
TFX
$5.94B
| $944K | ﹤0.01% |
3,520
-786
| -18% | -$211K |
|
2687
PUT
Paychex
PAYX
$44.5B
| $943K | ﹤0.01% |
13,800
| – | – |
|
2688
CALL
BioMarin Pharmaceuticals
BMRN
$12.8B
| $942K | ﹤0.01% |
10,000
| – | – |
|
2689
Korn Ferry
KFY
$4.33B
| $935K | ﹤0.01% |
15,092
+9,647
| +177% | +$542K |
|
2690
NeoGenomics
NEO
$2.16B
| $935K | ﹤0.01% |
+71,308
| New | +$785K |
|
2691
CALL
Fabrinet
FN
$15.5B
| $933K | ﹤0.01% |
25,300
-4,000
| -14% | -$137K |
|
|
MNK
2692
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $933K | ﹤0.01% |
50,000
+15,600
| +45% | +$248K |
|
2693
Lexicon Pharmaceuticals
LXRX
$1.04B
| $932K | ﹤0.01% |
77,636
+31,741
| +69% | +$325K |
|
|
CLVS
2694
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
| $932K | ﹤0.01% |
20,500
-14,500
| -41% | -$705K |
|
2695
CALL
State Street
STT
$53B
| $931K | ﹤0.01% |
10,000
| – | – |
|
2696
CALL
Wolfspeed
WOLF
$1.31B
| $931K | ﹤0.01% |
22,400
+10,000
| +81% | +$438K |
|
2697
Merit Medical Systems
MMSI
$5.44B
| $930K | ﹤0.01% |
18,169
-4,409
| -20% | -$218K |
|
2698
Digimarc Corp
DMRC
$131M
| $929K | ﹤0.01% |
34,672
+17,539
| +102% | +$495K |
|
2699
Graham Corp
GHM
$1.09B
| $929K | ﹤0.01% |
36,005
-7,977
| -18% | -$191K |
|
2700
PUT
Vulcan Materials
VMC
$35.5B
| $929K | ﹤0.01% |
+7,200
| New | +$888K |
|
Similar funds
David Shaw's Q2 2018 Portfolio in Review
As of Q2 2018, David Shaw held 4,066 positions worth $76.7B, up 4.4% from $73.5B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
David Shaw's Q2 2018 filing shows 622 new, 1,512 increased, 1,263 reduced and 399 closed positions. Its largest new stake was Evergy: 4,161,679 shares worth $234M. The largest sale was Time Warner Inc, an estimated $648M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- David Shaw's largest Q2 2018 buy was Evergy: 4,161,679 shares worth $234M.
- David Shaw added most to Amazon in Q2 2018, an estimated $696M increase.
- David Shaw's biggest Q2 2018 reduction was Merck, cutting an estimated $453M.
- David Shaw fully exited Time Warner Inc in Q2 2018, selling an estimated $648M.
- David Shaw's ten largest holdings make up 9.8% of its $76.7B portfolio in Q2 2018.
- David Shaw opened 622 new positions and closed 399 in Q2 2018.
- David Shaw's portfolio value rose 4.4% quarter-over-quarter to $76.7B.
Based on D.E. Shaw & Co's 13F filing for Q2 2018, filed 14 Aug 2018.